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Bioluminescence resonance energy transfer (BRET)-based biosensors have been exten-
sively used over the last decade to study protein–protein interactions and intracellular
signal transduction in living cells. In this review, we discuss the various BRET biosen-
sors that have been developed to investigate biology, pharmacology, and signaling of G
protein-coupled receptors (GPCRs). GPCRs form two distinct types of multiprotein sig-
nal transduction complexes based upon their inclusion of G proteins or β-arrestins that
can be differentially affected by drugs that exhibit functional selectivity toward G protein or
β-arrestin signaling. BRET has been especially adept at illuminating the dynamics of protein–
protein interactions between receptors, G proteins, β-arrestins, and their many binding
partners in living cells; as well as measuring the formation and accumulation of second
messengers following receptor activation. Speciﬁcally, we discuss in detail the application
of BRET to study dopamine and trace amine receptors signaling, presenting examples of
an exchange protein activated by cAMP biosensor to measure cAMP, β-arrestin biosen-
sors to determine β-arrestin recruitment to the receptor, and dopamine D2 receptor and
trace amine-associated receptor 1 biosensors to investigate heterodimerization between
them. As the biochemical spectrum of BRET biosensors expands, the number of signaling
pathways that can be measured will concomitantly increase.This will be particularly useful
for the evaluation of functional selectivity in which the real-time BRET capability to mea-
sure distinct signaling modalities will dramatically shorten the time to characterize new
generation of biased drugs. These emerging approaches will further expand the growing
application of BRET in the screening for novel pharmacologically active compounds.
Keywords: arrestins, GRKs, EPAC, cAMP, FRET, screening assay,TAAR1
INTRODUCTION
Bioluminescence resonance energy transfer (BRET) is a process
in which a non-radiative transfer of energy occurs between an
excited luminescent enzyme/substrate donor complex and a ﬂuo-
rescent molecular acceptor that are separated by less than 100 Å.
In many BRET studies published to date, the donors are variants
of the enzyme, Renilla reniformis luciferase (Rluc), the enzy-
matically cleaved chemical substrate is coelenterazine, and the
light emitting acceptors are variants of green ﬂuorescent proteins
(GFPs; Pﬂeger and Eidne, 2006). Degradation of a luminescent
substrate by Rluc excites the GFP which in turn emits ﬂuo-
rescence. Resonance energy transfer (RET) techniques such as
ﬂuorescence resonance energy transfer (FRET) and BRET have
become experimental techniques of choice for measuring consti-
tutive and dynamic protein–protein interactions and interrogating
changes in the activity of many biochemical signaling pathways,
with FRET having the advantage of allowing cellular localization
of the biological phenomenon that is studied. On the other side,
BRET has advantage over FRET since it does not require an exter-
nal illumination to initiate the energy transfer, which may lead
to high background noise resulting from direct excitation of the
acceptor or photobleaching. BRET experiments much like FRET
can be conducted under conditions that more closely reﬂect the
biochemical environments occurring in living organisms. As such,
experimental platforms for BRET measurements have included
model systems composed of bacteria, mammalian, and plant cells,
and over 400 BRET related studies have been published since the
ﬁrst publication of Kai transcription factor interactions in bacteria
(Xu et al., 1999). Over the last decade, the main usage of BRET has
resided into investigating various protein–protein interactions (see
Ayoub and Pﬂeger, 2010; Ferre et al., 2010; Lohse et al., 2012 for
review) with major usage in the ﬁeld of G protein-coupled recep-
tors (GPCRs). However,more recently, several studies have applied
BRET for the study of dynamic cellular processes, be it themodula-
tion of the interaction of two proteins following a pharmacological
treatment or the development of biosensors for various signaling
pathways. In this review, we will discuss the development of some
of these biosensors for the study of GPCRs. The term biosen-
sor in this review will be applied to pharmacologically responsive
interactions of GPCRs with other interacting proteins designed to
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study GPCR signaling pathways. We will however only brieﬂy dis-
cuss the numerous studies that have reported pharmacologically
evoked BRET variations on either homo or heteromeric GPCR
complexes as those have in large part been reviewed elsewhere
(Ayoub and Pﬂeger, 2010; Ferre et al., 2010; Lohse et al., 2012).
Speciﬁcally, we will illustrate why BRET biosensors have become
such an enabling technology for studying GPCR biochemistry in
cellulo by presenting their use in characterizing the pharmacology
and signaling of two important GPCRs implicated in monoamine
transmission, the trace amine-associated receptor 1 (TAAR1) and
dopamine D2 receptor (D2R).
BRET BETWEEN RECEPTORS, G PROTEINS AND EFFECTORS
The ﬁrst such study to utilize BRET to monitor the interaction
between a GPCR and a G protein examined the interaction of β2-
adrenergic receptor (β2AR) with Gαsβ1γ2 (Gales et al., 2005). The
β2AR was C-terminally tagged with Rluc, while the αs, β1 and γ2
were tagged with GFP10, a blue shifted variant of the GFP pro-
tein. Importantly, while the β1 and γ2 subunits were N-terminally
tagged with GFP10, for the αs, the GFP10 was inserted between
the helical and the GTPase domain of the protein in order to pre-
serve αs functionality. Interestingly, a basal BRET signal indicative
of constitutive interaction between all the tagged subunits and
the receptor was observed. This BRET signal could be further
enhanced with agonist stimulation when the heterotrimeric G
protein was expressed, indicating either an increase in interac-
tion between receptor and G proteins or a conformational change
within the heterotrimeric complex. Since this ﬁrst study, many
others have been conducted on various receptor/G protein com-
plexes, describing the kinetics, the orientation and the effects of
ligands on the G protein–receptor interaction (Ayoub et al., 2007,
2009; Hasbi et al., 2007; Audet et al., 2008; Harikumar et al., 2008;
Lohse et al., 2008; Kuravi et al., 2010; Oner et al., 2010; Busnelli
et al., 2012).
Other BRET studies have investigated the interaction of GPCR
with downstream effectors such as adenylyl cyclases or ion
channels. Using a BRET approach, a constitutive interaction
between β2AR–GFP andKir3.1–Rluc potassiumchannel or adeny-
lyl cyclase–Rluc was reported (Lavine et al., 2002). Importantly,
the Kir3 BRET studies required the expression of a functional
channel and therefore a signiﬁcant BRET signal for Kir3.1–Rluc
also required co-expression of the Kir3.2 or Kir3.4 subunits.
Interestingly, agonist stimulation did not modulate these interac-
tions, indicating that the complex between the receptor and these
effectors did not dissociate during signal transduction.
β-ARRESTIN-BASED BRET SENSORS
The ﬁrst and most reported BRET-based sensor studies for
GPCRs have been investigations into the dynamics of β-arrestin
recruitment. Non-visual arrestins, β-arrestin1 (arrestin-2) and
β-arrestin2 (arrestin-3), are cytosolic proteins that bind agonist
stimulated receptors. In a pioneering study, Barak et al. (1997)
showed that stimulation of β2AR with the full agonist isopro-
terenol resulted in the recruitment of GFP-tagged β-arrestin2
to the plasma membrane from a cytoplasmic localization. The
recruitment of β-arrestin to a receptor is a signal event that initi-
ates two important biological effects. First, β-arrestin recruitment
leads to the internalization of the receptor into endocytic vesicles.
Second, β-arrestin recruitment is associated with the stimulation
of additional signal transduction pathways that are G protein
independent (Lefkowitz and Shenoy, 2005). Over the years it
has become clear that G protein- and β-arrestin-dependent sig-
naling pathways may lead to different physiological effects. This
has led to the idea that novel therapeutic approaches can be pur-
sued based upon the selective modulation of either the G protein
or the β-arrestin-dependent pathway (Whalen et al., 2011). As
such, devising new approaches to interrogate β-arrestin signaling
becomes an important avenue for drug development. Consider-
ing the many advantages of BRET, the measurement of β-arrestin
recruitment to receptors using BRET became a complemen-
tary approach to the technique developed by Barak et al. (1997)
that measures β-arrestin redistribution by analyzing high content
images. The ﬁrst study investigating β-arrestin recruitment to a
GPCR using BRET employed a β-arrestin2–YFP molecule and
β2AR–Rluc (Angers et al., 2000; see Figure 1 for example and
principle). Since this seminal study, β-arrestin recruitment has
been reported in more than 30–40 manuscripts, where the time
course, dose response, ligand dependency, and effects of receptor
homo/hetero-oligomerization on recruitment have been assessed
(for reviews, see Pﬂeger and Eidne, 2003; Pﬂeger et al., 2007).
In addition, a β-arrestin2 recruitment approach by BRET was
also successfully used in a high-throughput screening (HTS) plat-
form to identify new antagonists of the chemokine CCR5 receptor
(Hamdan et al., 2005), demonstrating the versatility of this assay.
In order to better understand the conformational changes
incurred by β-arrestin2 upon its recruitment to the receptor,
Charest et al. (2005) developed a β-arrestin2 biosensor termed
double brilliance. The double brilliance is a single molecule
biosensor in which β-arrestin2 is tagged with Rluc and YFP at
the N and C terminus, respectively. The double brilliance can be
used to monitor stimulation of GPCRs, since agonist stimulation
of the receptors leads to an increase of the constitutive basal BRET
signal of the double brilliance. Interestingly, GPCR stimulation
does not always lead to an increase in the BRET signal of double
brilliance. For angiotensin AT1 receptor signaling, it was observed
that while stimulation with angiotensin increased the BRET sig-
nal, stimulation of the receptor with a β-arrestin-biased agonist
(SII), produced a decrease in the BRET signal of double bril-
liance (Shukla et al., 2008). A similar observation was made for the
parathyroid hormone receptor type 1 (PTH1R). Stimulation with
PTH-(1–34) led to an increase in the BRET signal and treatment
with (PTH-IA), a β-arrestin-biased ligand, resulted in a decrease in
the BRET signal (Shukla et al., 2008). These observations indicate
that β-arrestin can adopt multiple different conformations that
are dependent on the ligand that stimulates the receptor, and that
these changes can be probed using the double brilliance biosensor.
β-Arrestin2 is ubiquitinated following GPCRs activation and
in the case of many receptors this process has been shown to
be required for receptor endocytosis (Shenoy et al., 2001; Ahmed
et al., 2011; Shenoy and Lefkowitz, 2011). Two major classes of
GPCRs (class A and B) have been described with regard to the
stability of their interaction with β-arrestins. Class A receptors
form transient complexes, while class B receptors form stable
complexes with β-arrestins after receptor stimulation. It has been
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FIGURE 1 | Bioluminescence resonance energy transfer (BRET)
monitoring of β-arrestins recruitment to activated GPCRs. (A) Cartoon
of postulated molecular events following activation of a GPCR by agonist
that lead to recruitment of arrestin to phosphorylated receptor causing
related BRET signal. Arrestins can be tagged with different versions of
GFP (YFP, Citrine, or Venus; for review, see Pﬂeger and Eidne (2006)) and
GPCRs are tagged with Rluc to monitor intermolecular interaction by
BRET. (B)Titration curves of β-arrestin1–YFP recruitment to D2R–Rluc
with or without D2R agonist quinpirole. (C)Titration curves on β-arrestin2–YFP
recruitment to D2R–Rluc with or without D2R agonist quinpirole. (D)
Dose–response curve of quinpirole effect on β-arrestin2 recruitment
to D2R.
shown that stable β-arrestin receptor complexes lead to sustained
ubiquitination of β-arrestin while transient β-arrestin receptor
complexes result inmore temporary ubiquitination states (Shenoy
and Lefkowitz, 2011). ABRET-based ubiquitination assay has been
developed that allows the monitoring of β-arrestin ubiquitina-
tion in real time in live cells (Perroy et al., 2004). In these studies,
β-arrestin2 was tagged with Rluc while the GFP was fused to ubiq-
uitin. Agonist stimulation of both the β2AR, a class A receptor, and
vasopressinV2 receptor (V2R), a class B receptor, results in a dose-
dependent increase in BRET signal between Rluc–β-arrestin and
GFP–ubiquitin, indicative of receptor-inducedβ-arrestinubiquiti-
nation. Time course analysis of theBRET signal betweenβ-arrestin
and ubiquitin revealed that the signal was transient for β2AR stim-
ulated samples while persistent for the V2R stimulated sample
(Perroy et al., 2004). This observation is in agreement with prior
experiments describing the dynamics of β-arrestin ubiquitination
with class A and B receptors and demonstrates the utility of this
sensor for studying the dynamics of β-arrestin ubiquitination in
live cells.
Receptor interaction with G protein-coupled receptor kinases
(GRKs) has also been investigated using BRET sensors. GRKs are
a family of serine/threonine protein kinases that phosphorylate
agonist stimulated receptors and for the most part desensitize
their G protein signaling activity (Reiter and Lefkowitz, 2006).
The ﬁrst study utilizing BRET investigated the dynamics of an
interaction between the Rluc–oxytocin receptor (Rluc–OTR) with
GRK2–YFP (Hasbi et al., 2004). The authors showed that GRK2
is rapidly recruited to the receptor after agonist stimulation and
that after severalminutes of sustained stimulation the BRET signal
decreases, consistentwith the transient nature of theGRK/receptor
interaction. Interestingly, the kinetics of GRK2 recruitment to
OTR preceded β-arrestin2 recruitment to the same receptor sug-
gesting that in this case, GRK2-mediated phosphorylation of OTR
occurred before β-arrestin2 was recruited to the receptor. Other
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studies using BRET to investigate the interaction of GRKs with
various GPCRs can be found in the following references (Hutten-
rauch et al., 2005; Small et al., 2006; Jorgensen et al., 2008, 2011;
Namkung et al., 2009).
PKA cAMP BRET BIOSENSORS
By coupling to either stimulatory Gs or inhibitory Gi protein
pathways, many GPCRs modulate cAMP production, a second
messenger that directly affects the function of many regulatory
proteins. To study the dynamics of cAMP production, different
BRET biosensors have been developed. The ﬁrst BRET cAMP
biosensor was based on protein kinase A (PKA; Prinz et al., 2006).
PKA, a serine/threonine kinase, is composed of two regulatory and
two catalytic subunits that dissociate uponbinding of cAMP.There
are two major PKA isoforms (I and II) that are expressed in mam-
malian cells with distinct biochemical and cellular functions. Prinz
et al. (2006) created PKA fusion constructs by tagging the cat-
alytic subunit with GFP2 (GFP-C) and regulatory subunits RI and
RII with Rluc (RI–Rluc and RII–Rluc). Co-transfection of GFP-C
subunit with either RI–Rluc or RII–Rluc results in a constitutive
BRET signal that decreases in response to cAMP elevations from
forskolin/IBMX treatment. However, only the RII–Rluc/GFP-C
BRET sensor is sensitive to cAMP production by isoproterenol, a
β2AR agonist, indicating that only PKA isoform II is in the correct
spatial localization for detecting cAMP increases resulting from
plasma membrane GPCR activation. However, when cells were
treated with both isoproterenol and IBMX, both PKA isoform (RI
and RII) were able to pick up the cAMP production induced by
β2AR indicating that IBMX treatment alleviates the necessity for
proper spatial localization to detect cAMP changes. Nevertheless,
even in thepresence of IBMXthemagnitudeof change in theBRET
signal was greater from isoform II compared to isoform I, indicat-
ing that RII-based sensors may be more functionally sensitive and
suitable for following GPCR-induced cAMP signals.
Although the PKA-based cAMP BRET biosensor is a power-
ful tool, it has an inherent caveat in that it is an intermolecular
biosensor requiring the expression of two different proteins, i.e.,
regulatory and catalytic subunits. Therefore, a new generation
of less complex single molecule cAMP BRET biosensors was
developed from the guanine nucleotide exchange protein acti-
vated by cAMP (EPAC). To date two independent EPAC BRET
biosensors have been described and used to study the modula-
tion of the cAMP pathway by various GPCRs (Jiang et al., 2007;
Barak et al., 2008).
APPLICATION OF BRET BIOSENSORS FOR THE STUDY
OF D2R AND TAAR1
The recent development of BRET and FRET biosensors has
allowed the study of a variety of physiological processes, such
as formation of second messengers, protein kinases activity,
protein–protein interactions, and protein trafﬁcking (Vilardaga
et al., 2003; Ni et al., 2006; Ayoub and Pﬂeger, 2010; Milli-
gan, 2010; Lohse et al., 2012). With the application of different
biosensors to the same receptor it is also possible to monitor
the multidimensional complexity of signaling of a given recep-
tor under the same experimental conditions. For example, the
D2 dopamine receptor (D2R) is a Gi coupled receptor that is
known to decrease cAMP levels upon stimulation by an agonist
(Beaulieu and Gainetdinov, 2011). Recently, a new modality of
G protein-independent β-arrestin2-mediated signaling has been
described for D2R (Beaulieu et al., 2007; Beaulieu and Gainetdi-
nov, 2011). BothGprotein-dependent and -independent signaling
pathways play important roles in dopamine-related physiological
and pathological processes (Beaulieu et al., 2005, 2007; Beaulieu
and Gainetdinov, 2011). Using a heterologous expression system
and two different BRET biosensors, we assessed cAMP signaling
and β-arrestin2 recruitment following activation or blockade of
D2R (Masri et al., 2008). In another set of studies aimed at bet-
ter understanding of monoamine transmission, we used BRET
to study the signaling properties and pharmacology of TAAR1.
In recent years, the TAAR1 has attracted attention as a potential
new target for themodulation of the dopaminergic system (Linde-
mann et al., 2008; Sotnikova et al., 2009; Revel et al., 2011). Using
BRET assays, we have evaluated the ability of TAAR1 and D2R to
form a functional heterodimer and alter each other’s signaling and
functions (Espinoza et al., 2011).
USE OF EPAC cAMP BRET BIOSENSOR TO STUDY
D2R AND TAAR1
The cAMP EPAC biosensor used in our studies was originally
developed as a FRET biosensor (DiPilato et al., 2004) and later
adapted for BRET applications (Barak et al., 2008). In this sensor,
both the donor and the acceptor are located within the same pro-
tein leading to an intramolecular energy transfer. The sensor is
made of EPAC, a protein that changes conformation upon bind-
ing cAMP. The premise behind the original FRET biosensor was
to tag the full-length protein by a donor (enhanced cyan ﬂuores-
cent protein, ECFP) and an acceptor (Citrine) on each extremity
of the protein (see Figure 2 for example and principle). The
sensor was further improved by using a truncated form of the
protein, comprised only of the cAMP binding domain and named
ICUE2. ICUE2 was transformed in a BRET sensor by replacing
the ECFP with the Rluc (Barak et al., 2008). At resting levels, there
is considerable basal energy transfer between Rluc and Citrine
resulting in a high BRET ratio, suggesting that in the absence
of cAMP the donor and the acceptor are in close proximity. As
cAMP increases, BRET ratios decrease, presumably due to a con-
formational change leading to increased distance between the Rluc
and Citrine. As for other BRET sensors, the main advantage of
EPAC is the possibility to measure the ﬂuctuations of cAMP in
real time and so to evaluate the contribution and the kinetic of
different systems that modulate cAMP levels. GPCRs that cou-
ple to Gs or Gi are thus suitable targets for investigations with
this sensor. Importantly, the BRET response with this sensor is
reversible since the removal of the agonist or the addition of an
antagonist results in a decrease of the response (DiPilato et al.,
2004). Stimulation of both TAAR1 and β2AR leads to increases in
cAMP levels readily measurable with the EPAC biosensor (Barak
et al., 2008; Violin et al., 2008). But the degree of desensitization
of these two receptors is different, being stronger for the β2AR. In
comparison to β2AR, over-expressed TAAR1 has relatively minor
level of plasma membrane expression, having predominantly an
intracellular localization. Due to either poor surface expression
or the fact that TAAR1 may be less prone to desensitization, the
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FIGURE 2 | Bioluminescence resonance energy transfer (BRET) EPAC
biosensor for cAMP monitoring. (A) Cartoon of the postulated molecular
rearrangement of the full-length EPAC protein with and without intracellular
cAMP increase causing related BRET signal. EPAC, a protein that changes
conformation upon cAMP binding, was tagged with a BRET donor (Rluc)
and a BRET acceptor (YFP) on each extremity of the protein to monitor
intramolecular BRET signal. (B)Time course effects β-PEA in cells transiently
transfected with EPAC andTAAR1. BRET ratio is measured asYFP/Rluc ratio
and the readings are started right after β-PEA addition. Cells are exposed to
different concentration of β-PEA (from 1 nM to 100 μM) or control medium.
The decrease in BRET ratio indicates an increase in cAMP concentration.
β-PEA induces a robust increase in cAMP level that lasts along the duration
of the entire experiment (20 min). (C) Dose–response of β-PEA effect on
TAAR1-dependent cAMP accumulation after 10 min of stimulation.
over-expression of β-arrestin2 has substantially less of an effect on
the kinetic of cAMP response of TAAR1 in comparison to β2AR
(Barak et al., 2008).
Considering the simplicity of BRET experimental procedures it
is evident that the EPAC sensor is a suitable tool for medium/HTS
for identiﬁcation of ligands of GPCRs that modulate cAMP.
For example, we tested many potentially active compounds for
their activity at membrane-expressed human TAAR1, conﬁrming
activity of some of the already known ligands and discovering
interesting new ligands (Barak et al., 2008). In a follow-up study,
we used EPAC sensor to screen for novel TAAR1 ligands against
a limited library containing 1,000 drug-like compounds (data not
published). About 20 potentially active compounds were initially
identiﬁed but after excluding compounds that showed activity in
cells expressing only the EPAC, four were conﬁrmed as puta-
tive human TAAR1 agonists. Three of these compounds were
known agonists of TAAR1, tyramine, 3-methoxytyramine, and
4-methoxytyramine, thereby validating speciﬁcity and sensitivity
of this screening approach. Interestingly, the fourth compound
was guanabenz that was later identiﬁed, by another group, as one
of the most potent agonists of TAAR1 (Hu et al., 2009). In general,
comparing with a standard radioactive cAMP column chromatog-
raphy assay, the BRETmethodwas found to be qualitatively similar
but slightly more sensitive.
In another study, we used the EPAC biosensor to study the
functional interaction betweenTAAR1 andD2R and observed that
blockade of D2R selectively enhances TAAR1 signaling indicating
a functional interaction between these two receptors (Espinoza
et al., 2011). We have also used the EPAC sensor to evaluate the
ability of different antipsychotics to blockD2R-mediated signaling
(Masri et al., 2008). Almost all antipsychotics showed an intrinsic
activity as inverse agonists, with the exception of aripiprazole,
a known partial D2R agonist. However, against quinpirole, a
selective D2R agonist, the compounds blocked the response with
different potencies and afﬁnities, while aripiprazole’s maximum
efﬁcacy of blockade was only 30%. All these are examples of how
the EPAC sensor is a powerful tool for studying cAMP ﬂuctuations
in living cells.
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β-ARRESTIN2 RECRUITMENT STUDIES FOR D2R
β-Arrestins were originally identiﬁed for their role in desensitiz-
ing GPCRs while subsequent studies have shown that β-arrestins
can also activate signaling cascades independently of G proteins
by acting as multifunctional scaffolding proteins (for review:
Shenoy and Lefkowitz, 2011). Therefore, to fully characterize
the mode of action of GPCR ligands, it is useful to evaluate
their effects on both the G protein-mediated pathway and the
β-arrestin pathway. A study conducted using β-arrestin2 knock-
out mice demonstrated that D2R can engage the Akt/glycogen
synthase kinase 3 (GSK-3) signaling pathway by a mechanism
that involves a signaling complex comprised of β-arrestin2, Akt,
and the multimeric protein phosphatase PP2A (Beaulieu et al.,
2005). This signaling pathway is essential since it is involved in
the expression of some dopamine associated behaviors that are
sensitive to antipsychotic drugs (Beaulieu et al., 2004). In fact,
the clinical efﬁcacy of almost all antipsychotic drugs (typical and
atypical) is directly correlated with their binding afﬁnity to D2R
and their capacity to antagonize this receptor (Creese et al., 1976).
The activity of these compounds has been extensively studied for
cAMP signaling but little is known about ligand selectivity for β-
arrestin-mediated signaling pathways. As described above, using
BRET, it is possible tomonitor real-time translocationof β-arrestin
to an activated GPCR as well as to measure the effective dose
(EC50) of an agonist or the inhibitory concentration (IC50) of
different antagonists and compare their activity on this signaling
pathway.
We used the β-arrestin and the EPACBRETbiosensors to deﬁne
more precisely how antipsychotics affect dopamine D2 receptor
signaling. While antipsychotics had antagonistic properties with
very variable efﬁcacies and potencies regarding Gi/o-mediated
cAMP production, all these molecules were highly effective at
antagonizing β-arrestin2 translocation to D2R with potencies
between 3- and 150-fold higher than at the G protein-mediated
pathway (Masri et al., 2008). These results suggested that clini-
cally effective antipsychoticsmay act as preferential antagonists for
D2R/β-arrestin2-mediated signaling rather than Gi/o-mediated
signaling by this receptor. It is tempting to speculate that antipsy-
chotics may exert their therapeutic effects in part by blocking
β-arrestin2-mediated D2R signaling while inducing some of their
side effects through modulation of other pathways. This idea
was recently explored by using analogs of the atypical antipsy-
chotic aripiprazole. These functionally selective β-arrestin2-biased
D2R ligands exhibit antipsychotic activity in vivo and do not
induce catalepsy in wild type mice (Allen et al., 2011). Thus,
biased pharmacological approaches aimed at selectively target-
ing the β-arrestin2 signaling pathway activated by dopamine D2R
may provide safer and more effective antipsychotics and protect
against some of the motor side effects associated with this class
of drugs.
D2R AND TAAR1 HETERODIMERIZATION
Direct protein–protein interaction is a commonly accepted con-
cept in cell biology and in the recent years the possibility of homo-
or heterodimerization of GPCRs has been fully appreciated. Using
different techniques, it has been shown that many GPCRs exist as
homo-, heterodimers or even as oligomers and techniques such as
FRET and BRET have strongly contributed to the characterization
of these physiological phenomena. The interaction between two or
more GPCRs can alter important functions of these receptors such
as cell surface delivery, G protein coupling and pharmacology, to
name a few (Dalrymple et al., 2008; Milligan, 2010).
Intriguingly, when TAAR1 and D2R were co-expressed in
the same cells, TAAR1-mediated cAMP signaling was increased
when D2R receptors were blocked with the antagonist haloperidol
(Espinoza et al., 2011). This signaling enhancement was selective
for TAAR1 and did not occur with other Gs-coupled receptors.
One possibility that we explored was heterodimerization between
TAAR1 and D2R. Using BRET, we observed that TAAR1 and D2R
can indeed exist as heterodimers when co-expressed in HEK-293
cells (Espinoza et al., 2011). Since BRET, like other techniques,
has certain limitations, it was important to have appropriate
controls to verify the reliability of the interaction (Marullo and
Bouvier, 2007). We therefore performed BRET titration assays
with a constant amount of the donor fusion protein (TAAR1–
Rluc) and an increasing amount of the acceptor fusion protein
(D2–YFP). The hyperbolic curve obtained for TAAR1–Rluc and
D2–YFP,but not forD1–YFP, conﬁrmed the selectivity of the inter-
action between these two receptors (see Figure 3). Furthermore,
in a BRET competition assay, where an equivalent quantity of
untagged D2R was co-expressed with TAAR1–Rluc and D2–YFP,
the BRET signal was signiﬁcantly decreased, while expression of
untagged D1R had no effect on the BRET. Using a whole cell
ELISA, we also showed that TAAR1 and D2R can co-internalize
upon agonist stimulation of D2R, further conﬁrming the physical
interaction between the two receptors. Using cellular fractiona-
tion, we further noted that the heterodimer was mainly expressed
at the plasma membrane and that treatment with D2R antag-
onist haloperidol could almost completely abolish the BRET
signal from the heterodimer. These results suggest that haloperi-
dol treatment either leads to the disassembly of the dimer or
that this treatment induces a conformational change such that
the distance between the donor and acceptor ﬂuorophores are
increased to the point where there is a decline in energy trans-
fer. Notably, ligand-promoted BRET changes have been reported
for other GPCR homo/heterodimers as well (Dalrymple et al.,
2008; Milligan, 2009). Finally, we have observed some functional
consequences of the putative TAAR1–D2R interaction where in
TAAR1-KO animals, haloperidol-induced striatal c-Fos expres-
sion and cataleptic responses were signiﬁcantly reduced (Espinoza
et al., 2011).
CONCLUSION AND PERSPECTIVES
Bioluminescence resonance energy transfer biosensors have been
instrumental in advancing our understanding of GPCR signal
transduction by providing optical tools to study real-time inter-
actions between receptors, the recruitment of binding partners
to receptors, and variations in concentrations of second mes-
sengers generated downstream of receptors. Most importantly,
BRET studies are conducted in live cells and enable the study of
a wide variety of signaling systems to be probed under biolog-
ically relevant conditions, with minimal perturbation and in a
quantitative manner. GPCR-related BRET biosensors have already
establishedutility as screeningplatforms indrugdiscovery process.
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FIGURE 3 | Bioluminescence resonance energy transfer (BRET)
monitoring ofTAAR1 and D2R heterodimerization. (A) Cartoon of
postulated molecular events during heterodimerization of GPCRs causing
related BRET signal. TAAR1 is tagged with Rluc and D2R is tagged with
YFP to monitor intermolecular interaction between these two receptors.
(B) BRET titration curve of physical interaction betweenTAAR1–Rluc and
D2R–YFP. A ﬁxed amount of TAAR1–Rluc and increasing amount of
D2R–YFP were co-expressed in the same cells. BRET was measured
20 min after the addition of the substrate, coelenterazine h. To test
speciﬁcity of BRET signal betweenTAAR1 and D2R, BRET was also
measured betweenTAAR1–Rluc and increasing amount of D1R–YFP. The
hyperbolic shape of the curve indicates that TAAR1–Rluc and D2R–YFP
form a constitutive heterodimer when co-expressed in the same cells. A
linear increase in the BRET signal is observed betweenTAAR1–Rluc and
D1–YFP indicating a non-speciﬁc, bystander BRET between these
receptors.
At the same time, the number of BRET sensors described to
date represents only a small fraction of their potential applica-
tions in biology and the list of new sensors to interrogate various
signaling pathways and protein–protein interactions is rapidly
growing. In particular, we anticipate that a new generation of
BRET sensors will enable us to probe GPCR signaling in much
greater detail than currently possible; and potentially lead us to
new classes of “biased” ligands with unique therapeutic proﬁles
(Beaulieu et al., 2005, 2007; Masri et al., 2008; Beaulieu and
Gainetdinov, 2011; Whalen et al., 2011)
ACKNOWLEDGMENTS
This review was supported by research awards from F. Hoffmann -
La Roche Ltd (Basel, Switzerland) and Fondazione Compagnia di
San Paolo (Torino, Italy) to Raul R. Gainetdinov and Canadian
Institutes of Health Research (CIHR) to Ali Salahpour.
REFERENCES
Ahmed, M. R., Zhan, X., Song, X.,
Kook, S., Gurevich, V. V., and Gure-
vich, E. V. (2011). Ubiquitin lig-
ase parkin promotes Mdm2-arrestin
interaction but inhibits arrestin
ubiquitination. Biochemistry 50,
3749–3763.
Allen, J. A., Yost, J. M., Setola, V., Chen,
X., Sassano, M. F., Chen, M., Peter-
son, S., Yadav, P. N., Huang, X. P.,
Feng, B., Jensen, N. H., Che, X.,
Bai, X., Frye, S. V., Wetsel, W. C.,
Caron, M. G., Javitch, J. A., Roth,
B. L., and Jin, J. (2011). Discovery
of beta-arrestin-biased dopamine D2
ligands for probing signal transduc-
tion pathways essential for antipsy-
chotic efﬁcacy. Proc. Natl. Acad. Sci.
U.S.A. 108, 18488–18493.
Angers, S., Salahpour, A., Joly, E.,
Hilairet, S., Chelsky, D., Dennis, M.,
and Bouvier, M. (2000). Detection
of beta 2-adrenergic receptor dimer-
ization in living cells using biolumi-
nescence resonance energy transfer
(BRET). Proc. Natl. Acad. Sci. U.S.A.
97, 3684–3689.
Audet, N., Gales, C., Archer-Lahlou, E.,
Vallieres, M., Schiller, P. W., Bou-
vier, M., and Pineyro, G. (2008).
Bioluminescence resonance energy
transfer assays reveal ligand-speciﬁc
conformational changes within pre-
formed signaling complexes contain-
ing delta-opioid receptors and het-
erotrimeric G proteins. J. Biol. Chem.
283, 15078–15088.
Ayoub, M. A., Damian, M., Gespach,
C., Ferrandis, E., Lavergne, O., De
Wever, O., Baneres, J. L., Pin, J. P.,
and Prevost, G. P. (2009). Inhibition
of heterotrimeric G protein signal-
ing by a small molecule acting on
Galpha subunit. J. Biol. Chem. 284,
29136–29145.
Ayoub, M. A., Maurel, D., Binet,
V., Fink, M., Prezeau, L., Ansanay,
H., and Pin, J. P. (2007). Real-
time analysis of agonist-induced acti-
vation of protease-activated recep-
tor 1/Galphai1 protein complex
measured by bioluminescence res-
onance energy transfer in liv-
ing cells. Mol. Pharmacol. 71,
1329–1340.
www.frontiersin.org August 2012 | Volume 3 | Article 105 | 7
“fendo-03-00105” — 2012/8/28 — 11:01 — page 8 — #8
Salahpour et al. BRET biosensors for GPCRs
Ayoub, M. A., and Pﬂeger, K. D. (2010).
Recent advances in bioluminescence
resonance energy transfer technolo-
gies to study GPCR heteromeriza-
tion. Curr. Opin. Pharmacol. 10,
44–52.
Barak, L. S., Ferguson, S. S.,
Zhang, J., and Caron, M. G.
(1997). Abeta-arrestin/greenﬂuores-
cent protein biosensor for detecting
G protein-coupled receptor activa-
tion. J. Biol. Chem. 272, 27497–
27500.
Barak, L. S., Salahpour, A., Zhang, X.,
Masri, B., Sotnikova, T. D., Ram-
sey, A. J., Violin, J. D., Lefkowitz, R.
J., Caron, M. G., and Gainetdinov,
R. R. (2008). Pharmacological char-
acterization of membrane-expressed
human trace amine-associated recep-
tor 1 (TAAR1) by a bioluminescence
resonance energy transfer cAMP
biosensor. Mol. Pharmacol. 74,
585–594.
Beaulieu, J. M., and Gainetdinov, R.
R. (2011). The physiology, signal-
ing, and pharmacology of dopamine
receptors. Pharmacol. Rev. 63,
182–217.
Beaulieu, J. M., Gainetdinov, R. R., and
Caron, M. G. (2007). The Akt-GSK-
3 signaling cascade in the actions of
dopamine. Trends Pharmacol. Sci. 28,
166–172.
Beaulieu, J. M., Sotnikova, T. D., Mar-
ion, S., Lefkowitz, R. J., Gainetdinov,
R. R., and Caron, M. G. (2005).
An Akt/beta-arrestin 2/PP2A signal-
ing complex mediates dopaminergic
neurotransmission and behavior. Cell
122, 261–273.
Beaulieu, J. M., Sotnikova, T. D.,
Yao, W. D., Kockeritz, L., Wood-
gett, J. R., Gainetdinov, R. R., and
Caron, M. G. (2004). Lithium antag-
onizes dopamine-dependent behav-
iors mediated by an AKT/glycogen
synthase kinase 3 signaling cascade.
Proc. Natl. Acad. Sci. U.S.A. 101,
5099–5104.
Busnelli, M., Sauliere, A., Manning,
M., Bouvier, M., Gales, C., and
Chini, B. (2012). Functional selective
oxytocin-derived agonists discrimi-
nate between individual G protein
family subtypes. J. Biol. Chem. 287,
3617–3629.
Charest, P. G., Terrillon, S., and Bou-
vier, M. (2005). Monitoring agonist-
promoted conformational changes
of beta-arrestin in living cells by
intramolecular BRET. EMBO Rep. 6,
334–340.
Creese, I., Burt, D. R., and Snyder, S. H.
(1976). Dopamine receptor binding
predicts clinical and pharmacological
potencies of antischizophrenic drugs.
Science 192, 481–483.
Dalrymple, M. B., Pﬂeger, K. D., and
Eidne, K. A. (2008). G protein-
coupled receptor dimers: functional
consequences, disease states and
drug targets. Pharmacol. Ther. 118,
359–371.
DiPilato, L. M., Cheng, X., and Zhang,
J. (2004). Fluorescent indicators of
cAMP and Epac activation reveal dif-
ferential dynamics of cAMP signaling
within discrete subcellular compart-
ments. Proc. Natl. Acad. Sci. U.S.A.
101, 16513–16518.
Espinoza, S., Salahpour, A., Masri,
B., Sotnikova, T. D., Messa, M.,
Barak, L. S., Caron, M. G., and
Gainetdinov, R. R. (2011). Functional
interaction between trace amine-
associated receptor 1 and dopamine
D2 receptor. Mol. Pharmacol. 80,
416–425.
Ferre, S., Navarro, G., Casado, V.,
Cortes, A., Mallol, J., Canela, E. I.,
Lluis, C., and Franco, R. (2010). G
protein-coupled receptor heteromers
as new targets for drug development.
Prog. Mol. Biol. Transl. Sci. 91,
41–52.
Gales, C., Rebois, R. V., Hogue, M.,
Trieu, P., Breit, A., Hebert, T. E., and
Bouvier, M. (2005). Real-time mon-
itoring of receptor and G-protein
interactions in living cells. Nat. Meth-
ods 2, 177–184.
Hamdan, F. F., Audet, M., Garneau,
P., Pelletier, J., and Bouvier, M.
(2005). High-throughput screening
of G protein-coupled receptor antag-
onists using a bioluminescence res-
onance energy transfer 1-based beta-
arrestin2 recruitment assay. J. Biomol.
Screen. 10, 463–475.
Harikumar, K. G., Happs, R. M.,
and Miller, L. J. (2008). Dimeriza-
tion in the absence of higher-order
oligomerization of the G protein-
coupled secretin receptor. Biochim.
Biophys. Acta 1778, 2555–2563.
Hasbi, A., Devost, D., Laporte, S. A.,
and Zingg, H. H. (2004). Real-time
detection of interactions between
the human oxytocin receptor and
G protein-coupled receptor kinase-2.
Mol. Endocrinol. 18, 1277–1286.
Hasbi, A., Nguyen, T., Fan, T., Cheng,
R., Rashid, A., Alijaniaram, M.,
Rasenick, M. M., O’Dowd, B. F.,
and George, S. R. (2007). Trafﬁck-
ing of preassembled opioid mu-delta
heterooligomer-Gz signaling com-
plexes to the plasma membrane:
coregulation by agonists. Biochem-
istry 46, 12997–13009.
Hu, L. A., Zhou, T., Ahn, J., Wang, S.,
Zhou, J., Hu, Y., and Liu, Q. (2009).
Human and mouse trace amine-
associated receptor 1 have distinct
pharmacology towards endogenous
monoamines and imidazoline recep-
tor ligands. Biochem. J. 424,
39–45.
Huttenrauch, F., Pollok-Kopp, B., and
Oppermann, M. (2005). G protein-
coupled receptor kinases promote
phosphorylation and beta-arrestin-
mediated internalization of CCR5
homo- and hetero-oligomers. J. Biol.
Chem. 280, 37503–37515.
Jiang, L. I., Collins, J., Davis, R., Lin, K.
M., DeCamp, D., Roach, T., Hsueh,
R., Rebres, R. A., Ross, E. M., Taus-
sig, R., Fraser, I., and Sternweis, P.
C. (2007). Use of a cAMP BRET
sensor to characterize a novel regu-
lation of cAMP by the sphingosine
1-phosphate/G13 pathway. J. Biol.
Chem. 282, 10576–10584.
Jorgensen, R., Holliday, N. D., Hansen,
J. L., Vrecl, M., Heding, A.,
Schwartz, T. W., and Elling, C.
E. (2008). Characterization of G-
protein coupled receptor kinase inter-
action with the neurokinin-1 recep-
tor using bioluminescence resonance
energy transfer. Mol. Pharmacol. 73,
349–358.
Jorgensen, R., Norklit Roed, S., Heding,
A., and Elling, C. E. (2011). Beta-
arrestin2 as a competitor for GRK2
interaction with the GLP-1 receptor
upon receptor activation. Pharmacol-
ogy 88, 174–181.
Kuravi, S., Lan, T. H., Barik, A., and
Lambert, N. A. (2010). Third-party
bioluminescence resonance energy
transfer indicates constitutive associ-
ation of membrane proteins: appli-
cation to class a g-protein-coupled
receptors and g-proteins. Biophys. J.
98, 2391–2399.
Lavine, N., Ethier, N., Oak, J. N., Pei,
L., Liu, F., Trieu, P., Rebois, R. V.,
Bouvier, M., Hebert, T. E., and Van
Tol, H. H. (2002). G protein-coupled
receptors form stable complexes with
inwardly rectifying potassium chan-
nels and adenylyl cyclase. J. Biol.
Chem. 277, 46010–46019.
Lefkowitz, R. J., and Shenoy, S. K.
(2005). Transduction of receptor sig-
nals by beta-arrestins. Science 308,
512–517.
Lindemann, L., Meyer, C. A., Jeanneau,
K., Bradaia, A., Ozmen, L., Blueth-
mann, H., Bettler, B., Wettstein,
J. G., Borroni, E., Moreau, J. L.,
and Hoener, M. C. (2008). Trace
amine-associated receptor 1 modu-
lates dopaminergic activity. J. Phar-
macol. Exp. Ther. 324, 948–956.
Lohse, M. J., Hein, P., Hoffmann,
C., Nikolaev, V. O., Vilardaga, J. P.,
and Bunemann, M. (2008). Kinetics
of G-protein-coupled receptor sig-
nals in intact cells. Br. J. Pharmacol.
153(Suppl. 1), S125–S132.
Lohse, M. J., Nuber, S., and
Hoffmann, C. (2012). Fluores-
cence/bioluminescence resonance
energy transfer techniques to study
G-protein-coupled receptor activa-
tion and signaling. Pharmacol. Rev.
64, 299–336.
Marullo, S., and Bouvier, M.
(2007). Resonance energy transfer
approaches in molecular pharmacol-
ogy and beyond. Trends Pharmacol.
Sci. 28, 362–365.
Masri, B., Salahpour, A., Didrik-
sen, M., Ghisi, V., Beaulieu,
J. M., Gainetdinov, R. R., and
Caron, M. G. (2008). Antagonism of
dopamine D2 receptor/beta-arrestin
2 interaction is a common property
of clinically effective antipsychotics.
Proc. Natl. Acad. Sci. U.S.A. 105,
13656–13661.
Milligan, G. (2009). G protein-coupled
receptor hetero-dimerization: contri-
bution to pharmacology and func-
tion. Br. J. Pharmacol. 158, 5–14.
Milligan, G. (2010). The role of dimeri-
sation in the cellular trafﬁcking of
G-protein-coupled receptors. Curr.
Opin. Pharmacol. 10, 23–29.
Namkung, Y., Dipace, C., Javitch,
J. A., and Sibley, D. R. (2009).
G protein-coupled receptor kinase-
mediated phosphorylation regulates
post-endocytic trafﬁcking of the D2
dopamine receptor. J. Biol. Chem.
284, 15038–15051.
Ni,Q., Titov,D.V., and Zhang, J. (2006).
Analyzing protein kinase dynamics
in living cells with FRET reporters.
Methods 40, 279–286.
Oner, S. S., Maher, E. M., Breton,
B., Bouvier, M., and Blumer, J.
B. (2010). Receptor-regulated inter-
action of activator of G-protein
signaling-4 and Galphai. J. Biol.
Chem. 285, 20588–20594.
Perroy, J., Pontier, S., Charest, P. G.,
Aubry, M., and Bouvier, M. (2004).
Real-time monitoring of ubiquitina-
tion in living cells by BRET. Nat.
Methods 1, 203–208.
Pﬂeger, K. D., Dalrymple, M. B.,
Dromey, J. R., and Eidne, K.
A. (2007). Monitoring interactions
between G-protein-coupled recep-
tors and beta-arrestins. Biochem. Soc.
Trans. 35, 764–766.
Pﬂeger, K. D., and Eidne, K. A.
(2003). New technologies: biolumi-
nescence resonance energy transfer
(BRET) for the detection of real
time interactions involvingG-protein
coupled receptors. Pituitary 6,
141–151.
Pﬂeger, K. D., and Eidne, K. A.
(2006). Illuminating insights into
protein–protein interactions using
bioluminescence resonance energy
Frontiers in Endocrinology | Molecular and Structural Endocrinology August 2012 | Volume 3 | Article 105 | 8
“fendo-03-00105” — 2012/8/28 — 11:01 — page 9 — #9
Salahpour et al. BRET biosensors for GPCRs
transfer (BRET). Nat. Methods 3,
165–174.
Prinz, A., Diskar, M., Erlbruch, A.,
and Herberg, F. W. (2006). Novel,
isotype-speciﬁc sensors for protein
kinaseA subunit interaction based on
bioluminescence resonance energy
transfer (BRET). Cell Signal. 18,
1616–1625.
Reiter, E., and Lefkowitz, R. J. (2006).
GRKs and beta-arrestins: roles in
receptor silencing, trafﬁcking and sig-
naling. Trends Endocrinol. Metab. 17,
159–165.
Revel, F. G., Moreau, J. L., Gainetdinov,
R. R., Bradaia, A., Sotnikova, T. D.,
Mory, R., Durkin, S., Zbinden, K.
G., Norcross, R., Meyer, C. A., Met-
zler, V., Chaboz, S., Ozmen, L., Trube,
G., Pouzet, B., Bettler, B., Caron, M.
G., Wettstein, J. G., and Hoener, M.
C. (2011). TAAR1 activation mod-
ulates monoaminergic neurotrans-
mission, preventing hyperdopamin-
ergic and hypoglutamatergic activity.
Proc. Natl. Acad. Sci. U.S.A. 108,
8485–8490.
Shenoy, S. K., and Lefkowitz, R.
J. (2011). β-Arrestin-mediated
receptor trafﬁcking and signal trans-
duction. Trends Pharmacol. Sci. 32,
521–533.
Shenoy, S. K.,McDonald, P. H., Kohout,
T.A., and Lefkowitz, R. J. (2001). Reg-
ulation of receptor fate by ubiquiti-
nation of activated beta 2-adrenergic
receptor and beta-arrestin. Science
294, 1307–1313.
Shukla, A. K., Violin, J. D., Whalen,
E. J., Gesty-Palmer, D., Shenoy, S.
K., and Lefkowitz, R. J. (2008).
Distinct conformational changes in
beta-arrestin report biased agonism
at seven-transmembrane receptors.
Proc. Natl. Acad. Sci. U.S.A. 105,
9988–9993.
Small, K. M., Schwarb, M. R., Glinka,
C., Theiss, C. T., Brown, K. M.,
Seman, C. A., and Liggett, S. B.
(2006). Alpha2A- and alpha2C-
adrenergic receptors form homo-
and heterodimers: the heterodimeric
state impairs agonist-promoted GRK
phosphorylation and beta-arrestin
recruitment. Biochemistry 45,
4760–4767.
Sotnikova, T. D., Caron, M. G., and
Gainetdinov, R. R. (2009). Trace
amine-associated receptors as emerg-
ing therapeutic targets. Mol. Pharma-
col. 76, 229–235.
Vilardaga, J. P., Bunemann, M., Krasel,
C., Castro, M., and Lohse, M. J.
(2003). Measurement of the mil-
lisecond activation switch of G
protein-coupled receptors in liv-
ing cells. Nat. Biotechnol. 21,
807–812.
Violin, J. D., DiPilato, L. M., Yildirim,
N., Elston, T. C., Zhang, J.,
and Lefkowitz, R. J. (2008). β2-
Adrenergic receptor signaling and
desensitization elucidated by quan-
titative modeling of real time cAMP
dynamics. J. Biol. Chem. 283, 2949–
2961.
Whalen, E. J., Rajagopal, S., and
Lefkowitz, R. J. (2011). Therapeu-
tic potential of beta-arrestin- and G
protein-biased agonists. Trends Mol.
Med. 17, 126–139.
Xu, Y., Piston, D. W., and Johnson, C.
H. (1999). A bioluminescence reso-
nance energy transfer (BRET) system:
application to interacting circadian
clock proteins. Proc. Natl. Acad. Sci.
U.S.A. 96, 151–156.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 01 June 2012; accepted: 11
August 2012; published online: 29 August
2012.
Citation: Salahpour A, Espinoza S, Masri
B, Lam V, Barak LS and Gainetdinov RR
(2012) BRET biosensors to study GPCR
biology, pharmacology, and signal trans-
duction. Front. Endocrin. 3:105. doi:
10.3389/fendo.2012.00105
This article was submitted to Frontiers in
Molecular and Structural Endocrinology,
a specialty of Frontiers in Endocrinology.
Copyright © 2012 Salahpour, Espinoza,
Masri, Lam, Barak and Gainetdi-
nov. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the origi-
nal authors and source are credited and
subject to any copyright notices concern-
ing any third-party graphics etc.
www.frontiersin.org August 2012 | Volume 3 | Article 105 | 9
